Nxera signs $1.47bn AbbVie licensing deal pharmatimes.com/uncategorized/…
pharmatimes.com Nxera signs $1.47bn AbbVie licensing deal - PharmaTimes Agreement covers IBD drug candidate Latest posts 5
pharmatimes.com Nxera signs $1.47bn AbbVie licensing deal - PharmaTimes Agreement covers IBD drug candidate First patient dosed in rectal cancer BT-001 trial pharmatimes.com/news/first-pat…
pharmatimes.com First patient dosed in rectal cancer BT-001 trial - PharmaTimes Phase 1 study targets hard-to-treat patients Teva expands biosimilars alliance with Samsung Bioepis pharmatimes.com/uncategorized/…
pharmatimes.com Teva expands biosimilars alliance with Samsung Bioepis - PharmaTimes Agreement covers two FDA-approved immunology treatments Myeloma fund launches with £15m initial backing pharmatimes.com/uncategorized/…
pharmatimes.com Myeloma fund launches with £15m initial backing - PharmaTimes Philanthropy initiative targets treatment innovation Santersus advances nucleoCapture into pivotal sepsis study pharmatimes.com/news/santersus…
pharmatimes.com Santersus advances nucleoCapture into pivotal sepsis study - PharmaTimes Axcellant appointed global CRO for multinational trial